<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702739</url>
  </required_header>
  <id_info>
    <org_study_id>FDAAA 801</org_study_id>
    <nct_id>NCT02702739</nct_id>
  </id_info>
  <brief_title>Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients</brief_title>
  <acronym>HCV</acronym>
  <official_title>Efficacy and Safety of Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly Cirrhotic Patients: a Real Life Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Camillo Forlanini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Camillo Forlanini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proportion of HCV infected patients over age 65 years in Western countries is increasing.
      This growth and the advent of new antiviral therapy bring into the question the real world
      efficacy and safety of the combination of Sofosbuvir and Simeprevir (SOF/SMV) plus a flat
      dose of ribavirin (RBV) in elderly patients compared to younger patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proportion of HCV infected patients over age 65 years in Western countries is increasing.
      This growth and the advent of new antiviral therapy bring into the question the real world
      efficacy and safety of the combination of Sofosbuvir and Simeprevir (SOF/SMV) plus a flat
      dose of ribavirin (RBV) in elderly patients (Group II) compared to younger patients (Group I)
      Multicenter, real world investigation study of once daily treatment with SOF 400 mg + SMV 150
      mg with a flat dose of RBV 800 mg/day for a duration of 12 weeks in treatment naïve or
      experienced HCV genotype 1-infected patients with compensated cirrhosis.To evaluate efficacy,
      tollerability and safety of SOF/SMV/RBV in two different Group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response week 12 after the end of treatment</measure>
    <time_frame>up 12 weeks</time_frame>
    <description>to evaluate the efficacy in term of sustained virological response after 12 weeks from the end of treatment in the two Groups of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and severe adverse events during the treatment period</measure>
    <time_frame>up 12 weeks</time_frame>
    <description>To report Adverse events and severe adverse events during the treatment period in the two Groups of patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Group I (&lt;65 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (&gt;65 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks</intervention_name>
    <description>Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks</description>
    <arm_group_label>Group I (&lt;65 years)</arm_group_label>
    <arm_group_label>Group II (&gt;65 years)</arm_group_label>
    <other_name>Sovaldi Olysio Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naive or experienced patients with genotype 1 compensated cirrhosis

        Exclusion Criteria:

          -  HIV and hepatitis B infection, active hepatocellular carcinoma (HCC), decompensated
             cirrhosis, history of organ transplant, severe psychiatric disorders or treatment with
             drugs that showed an interaction with antiviral treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriano M Pellicelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>AO San Camillo Forlanini ROme ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AO San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pellicelli AM, Romano M, Guarascio P, Vignally P. Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis? J Hepatol. 2012 Sep;57(3):704-5. doi: 10.1016/j.jhep.2012.03.008. Epub 2012 Apr 14.</citation>
    <PMID>22510262</PMID>
  </reference>
  <results_reference>
    <citation>Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416.</citation>
    <PMID>26890629</PMID>
  </results_reference>
  <results_reference>
    <citation>Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004. Epub 2014 Jul 3.</citation>
    <PMID>24997638</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Camillo Forlanini</investigator_affiliation>
    <investigator_full_name>Adriano Pellicelli</investigator_full_name>
    <investigator_title>Director Liver Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

